BSR DMARD monitoring guidelines: sulfasalazine SIR, Regarding the recommendations for monitoring SSZ, I and my colleagues [1] recently reported a series of patients with serious hepatotoxicity associated with SSZ including two patients with liver failure. Some, but not all, of our patients met the criteria for the DRESS (drug rash with eosinophilia and systemic symptoms) syndrome. This term, we feel, is unnecessarily restrictive and other published descriptors for early toxicity with SSZ include the terms 'three week syndrome' or 'sulphone syndrome'. The purpose of this comment is to highlight that serious and potentially lifethreatening toxicity with SSZ arises within 6 weeks of therapy. Whilst such toxicity is uncommon (we estimated that the frequency of hepatitis with SSZ was 0.4% in our population) it is clear that a recommendation to monitor blood every 4 weeks, according to the new BSR/BHPR guidelines [2] , is likely to lead to a delay in recognizing such toxicity. Our own local guidance recommends testing of blood every 2 weeks for the first 3 months of treatment [3] . Patients are also warned, when being counselled about treatment, to discontinue the drug if they develop a rash or become generally unwell and to seek medical advice. 320) , anti-Ro antibodies (>100 u/ml, normal range 0-20) and anti-thyroid microsomal antibodies were positive. Anti-double-stranded DNA, aCLs, ANCAs, anti-mitochondrial and anti-liver/kidney microsomal antibodies were negative. Percutaneous liver core biopsy showed mild mononuclear cell infiltrate in the portal tracts, moderate interface hepatitis and focal necrosis and hepatocyte apoptosis within parenchymal areas, features consistent with autoimmune hepatitis. Whilst C3 and C4 levels were normal, total complement haemolytic activity (CH50) was repeatedly absent indicating possible complement deficiency state. Reconstitution assays were performed in which sera with selective defects of complement components or subunits were mixed with the patient sera and the haemolytic activity of the resultant mixture measured (Table 1) . Serum deficient in either the C8 subunit of the C8 protein or the classical pathway component C1q did not restore haemolytic activity to the patient's sera. Normal CH50 was only restored following the addition of both C8 and C1q to the patient's sera. Antigenic assays confirmed complete absence of both C8 and C1q in our patient ( Table 1 ). The genetic basis of the C8 c Confirmed using Sfcl RFLP assay [7] . Amino acid numbering refers to the translational start site (methionine is one), G: glycine; R: arginine; Term: stop codon.
